Key Highlights
- H1 FY26 Revenue rose 37% to £4.2 million, with the adjusted EBITDA loss narrowing to £1.7 million from £1.9 million.
- Management guided that H2 FY26 should turn EBITDA and operating cash-flow positive for the first time.
- Cash stood at £3.7 million at 31 December 2025, up from £1.9 million, boosted by a £3.2 million October 2025 fundraise.
- Full-year FY26 revenue guidance was maintained at £12.6 million, including £12.2 million of contract revenue.
- Contract development revenue grew 75% and regulatory services revenue grew 49% year-on-year.
The AIM-listed lateral flow diagnostics specialist reported revenue up 37% to £4.2 million in the six months to December 2025, narrowed its EBITDA loss, and told investors it expects the second half of its financial year to turn EBITDA and cash-flow positive.
Abingdon Health (LSE:ABDX), the York-based contract developer and manufacturer of lateral flow rapid tests, published its half-year financial report on 17 March 2026, covering the six months to 31 December 2025. Revenue rose 37% year-on-year, alongside a narrower operating loss and a strengthened cash position. Management also guided that the second half of the current financial year, running to 30 June 2026, should be EBITDA and operating cash-flow positive — a milestone the small-cap has been building towards for several years.
What Happened
In its interim statement, Abingdon Health reported revenue of £4.2 million for the first half of its 2026 financial year (H1 FY26), up from £3.1 million a year earlier, a rise of 37%. Including £0.216 million of grant-funded income from a UKRI-backed malaria diagnostics project, total revenues reached £4.5 million, up 45%.
The adjusted EBITDA loss narrowed to £1.7 million, from £1.9 million in H1 FY25. Crucially, the company told shareholders it expects H2 FY26 to be EBITDA and operating cash-flow positive — an expectation rather than a reported outcome, since the interim report only covers the first six months. Management also said it expects the full-year FY26 EBITDA loss to show "significant improvement" versus the £2.6 million loss reported for FY25.
Cash and equivalents stood at £3.7 million at 31 December 2025, up from £1.9 million at 30 June 2025, boosted by £3.2 million of net proceeds from an October 2025 fundraise. The company reiterated full-year FY26 revenue guidance of £12.6 million, comprising £12.2 million of contract revenues and £0.4 million of grant income.
Why It Matters
Abingdon Health occupies a niche but useful position in UK life sciences: it develops and manufactures lateral flow tests — the technology behind home Covid-19 and pregnancy tests — for customers who need speed and regulatory expertise rather than in-house Manufacturing capacity. Since pandemic-era Demand for Covid tests evaporated, the company has had to prove it can build a sustainable, diversified revenue base from contract development, manufacturing and regulatory consulting work. Sustained revenue growth alongside a shrinking cash burn is the clearest evidence yet that this transition is working, and it matters to small-cap investors watching whether AIM-listed life sciences companies can reach profitability without repeated dilutive fundraising.
Latest Financial and Operational Performance
The interim results showed growth across most service lines. Contract development revenue rose to £1.4 million from £0.8 million, a 75% increase, while regulatory services revenue grew 49% to £1.9 million from £1.3 million. Contract manufacturing revenue was flat at £0.5 million, and product sales dipped slightly to £0.4 million from £0.5 million.
The company also flagged that revenues previously expected from its Find Out From Home (FOFH) joint venture in H1 or H2 FY26 have now slipped into FY27, attributed to a customer's ongoing fundraising process rather than any issue with Abingdon's delivery.
On the contract-win front, the period included a US$2 million contract announced in November 2025 for development, scale-up and technical transfer of a semi-quantitative, multiplex lateral flow test system, and — shortly after the half-year end — a further US$2.5 million contract announced on 12 March 2026 for technical support on a clinical self-test's development and regulatory submission. A more-than-£1 million deal with CS Lifesciences, a major global diagnostics company first announced in January 2025, continued to progress.
In May 2026 the company also secured a Business Development Tax Credit Agreement with the Wisconsin Economic Development Corporation, worth up to US$370,000 over three years, tied to Job creation and Capital Investment at its Madison, Wisconsin Facility — modest but useful support for its North American expansion.
Key Numbers
- H1 FY26 reported revenue: £4.2 million, up 37% (H1 FY25: £3.1 million)
- H1 FY26 total revenue including grants: £4.5 million, up 45%
- H1 FY26 adjusted EBITDA loss: £1.7 million (H1 FY25: £1.9 million loss)
- FY25 full-year EBITDA loss: £2.6 million (restated basis cited in H1 FY26 report)
- Cash at 31 December 2025: £3.7 million (30 June 2025: £1.9 million)
- October 2025 fundraise: £3.2 million net proceeds
- FY26 revenue guidance maintained at £12.6 million (£12.2m contract revenue plus £0.4m grants)
Growth Opportunities
Abingdon Health's growth case rests on deepening its role as an outsourced development and manufacturing partner as pharmaceutical and diagnostics companies increasingly favour point-of-care and self-testing formats over laboratory-based diagnostics. Its contract development and regulatory services lines, which grew fastest in H1 FY26, position it to capture demand from companion diagnostics and self-test programmes. The pipeline of US dollar-denominated contracts, including two multi-million-dollar deals signed either side of the half-year, suggests a broadening customer base beyond the UK and Europe, supported by its Wisconsin facility. The deferred, not cancelled, FOFH joint-venture revenues are a further lever once that partner completes its fundraising.
Risks Investors Should Know
The company remains loss-making at the EBITDA level and has relied on external fundraising, including raises in August 2024 and October 2025, to fund Working Capital — a pattern that could recur if the promised H2 swing to profitability slips. Revenue is concentrated in a small number of large contracts, so delays such as the FOFH slippage into FY27 can move the needle materially in any given period. As a sub-scale AIM company in a competitive CDMO market, Abingdon Health also faces currency exposure from its growing US dollar contract book and execution risk in scaling its young US operation.
What to Watch Next
Investors should watch for the full-year FY26 results, expected after the 30 June 2026 year-end, to confirm whether H2 delivered the promised EBITDA and cash-flow positive performance and whether the £12.6 million revenue guidance was met. Progress on the FOFH joint venture's fundraising, further contract wins, and expansion at the Wisconsin facility are also worth monitoring as indicators of whether growth can be sustained into FY27.
Outlook
Abingdon Health's (LSE:ABDX) half-year figures show a company narrowing its losses while growing revenue at a healthy clip, underpinned by demand for its contract development and regulatory services. The promised swing to H2 EBITDA profitability has not yet been reported — it remains guidance, not an achieved fact — but the trajectory, combined with a stronger cash position after October's fundraise, gives the company a credible platform to make that case at its next full-year results.






Please wait processing your request...